Written by: Parker Davis Since Pfizer and Moderna received Emergency Use Authorization from the FDA for administration of their COVID-19 vaccines back in December, we have witnessed the beginnings of a vaccination campaign of unprecedented proportions. The first dose was given on December 8, 2020 to a woman in the UK, followed shortly thereafter by the first administration in the US on December 14. As of January 14, 2021, more than 35 million doses of the COVID-19 vaccine have been administered worldwide, 11.9 million of which were in the US, according to Bloomberg.com (this figure is a …
Despite a rocky start, AstraZeneca tosses its hat into the COVID vaccine ring
In addition to Pfizer/BioNTech announcing their vaccine as being up to 95% effective in Phase 3 trials, Moderna and the University of Oxford partnered with AstraZeneca have added their names to the list of published vaccine efficacy data. Astonishingly, Moderna has reported in a news update that its vaccine is about 94% effective in preventing COVID-19, and recent reports indicate that not a single volunteer in their trial developed severe symptoms (Cohen, 2020). What’s more, early data from Phase 1 and 2 trials indicate that these vaccines may produce robust efficacy in preventing COVID-19 …
Pfizer and BioNTech Vaccine Efficacy, Remdesivir officially FDA approved, and Bamlanivimab gains EUA
Over the previous month, there have been many exciting advances in the arena of COVID-19 clinical trials. To start, recently Pfizer and BioNTech announced 90% efficacy (at 7 days post the second dose) in their BNT162b2 COVID-19 mRNA vaccine candidate. It is important to remember that these patients are not having their SARS-CoV-2 antibodies titers checked, rather the reported efficacy is based on the development of SARS-CoV-2 post treatment in the placebo and vaccine groups. Also of note is the timing at which this COVID-19 vaccine operates. It is a two dose vaccine separated by approximately …